Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre

The 5 year survival was 13%, and median survival 17 months. Treatment mortality was 0%. Patients that responded to treatment (40%) had a median survival of 26 months. TAI provides good palliation but selection of patients is crucial.